Cirius Therapeutics Stock

ciriustx.comBioTechFounded: 2015Funding to Date: $68.9MM

Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin sensitizer is used to treat nonalcoholic steatohepatitis which is characterized by buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.

Register for Details

For more details on financing and valuation for Cirius Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Robert Baltera Jr.
Chief Executive Officer, President and Board Member
Brian Farmer
Chief Financial Officer and Chief Business Officer
Jerry Colca Ph.D
Chief Scientific Officer
Howard Dittrich MD
Chief Medical Officer

Board Members

Daniel Estes Ph.D
Frazier Healthcare Partners
David Van Andel
Dennis Fenton Ph.D
Elaine Sun
Michael Jandernoa
Nilesh Kumar Ph.D
Novo Holdings
Robert Baltera Jr.
Robert Zerbe

Other companies like Cirius Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Cirius Therapeutics didn't wait for the government shutdown to end before it filed its IPO in January. It was, as JP Morgan analysts had predicted the month prior,